Azeliragon is an investigational small-molecule inhibitor of the receptor for advanced glycation end products (RAGE) that has been studied for its therapeutic potential in neurodegenerative conditions,… Read more
Azeliragon is an investigational small-molecule inhibitor of the receptor for advanced glycation end products (RAGE) that has been studied for its therapeutic potential in neurodegenerative conditions, such as Alzheimer’s disease, and various oncology applications. This category provides a comprehensive selection of reference standards designed to support the rigorous analytical requirements of pharmaceutical development and quality control. Laboratories utilize these compounds, including the parent API, related impurities, metabolites, and stable isotope labelled versions, for critical tasks such as impurity profiling and the validation of complex analytical methods. By providing well-characterized materials for accurate quantification, these standards assist researchers in ensuring reproducible results throughout the drug development lifecycle. Whether utilized for method development or routine batch testing, these reference compounds are essential tools for maintaining high standards in preclinical and clinical research settings.